327 related articles for article (PubMed ID: 32474655)
1. Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies.
Zhu L; Zhang C; Lü X; Song C; Wang C; Zhang M; Xie Y; Schaefer HF
J Mol Model; 2020 May; 26(6):162. PubMed ID: 32474655
[TBL] [Abstract][Full Text] [Related]
2. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
3. Computational analysis of drug resistance of taxanes bound to human β-tubulin mutant (D26E).
Uba AI; Bui-Linh C; Thornton JM; Olivieri M; Wu C
J Mol Graph Model; 2023 Sep; 123():108503. PubMed ID: 37209440
[TBL] [Abstract][Full Text] [Related]
4. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF
Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
[TBL] [Abstract][Full Text] [Related]
5. Elucidating the mechanism of action of the clinically approved taxanes: a comprehensive comparison of local and allosteric effects.
Churchill CD; Klobukowski M; Tuszynski JA
Chem Biol Drug Des; 2015 Nov; 86(5):1253-66. PubMed ID: 26032329
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Tripathi S; Srivastava G; Sharma A
Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
[TBL] [Abstract][Full Text] [Related]
7. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of resistance to cabazitaxel.
Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
[TBL] [Abstract][Full Text] [Related]
9. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
[TBL] [Abstract][Full Text] [Related]
10. Designing and Testing of Novel Taxanes to Probe the Highly Complex Mechanisms by Which Taxanes Bind to Microtubules and Cause Cytotoxicity to Cancer Cells.
St George M; Ayoub AT; Banerjee A; Churchill CD; Winter P; Klobukowski M; Cass CE; Ludueña RF; Tuszynski JA; Damaraju S
PLoS One; 2015; 10(6):e0129168. PubMed ID: 26052950
[TBL] [Abstract][Full Text] [Related]
11. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach.
Kumbhar BV; Bhandare VV; Panda D; Kunwar A
J Biomol Struct Dyn; 2020 Feb; 38(2):426-438. PubMed ID: 30831055
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
Sobue S; Mizutani N; Aoyama Y; Kawamoto Y; Suzuki M; Nozawa Y; Ichihara M; Murate T
Biochem Biophys Res Commun; 2016 Oct; 479(4):808-813. PubMed ID: 27687545
[TBL] [Abstract][Full Text] [Related]
13. Interaction of microtubule depolymerizing agent indanocine with different human αβ tubulin isotypes.
Kumbhar BV; Panda D; Kunwar A
PLoS One; 2018; 13(3):e0194934. PubMed ID: 29584771
[TBL] [Abstract][Full Text] [Related]
14. Insights into the interaction of discodermolide and docetaxel with tubulin. Mapping the binding sites of microtubule-stabilizing agents by using an integrated NMR and computational approach.
Canales A; Rodríguez-Salarichs J; Trigili C; Nieto L; Coderch C; Andreu JM; Paterson I; Jiménez-Barbero J; Díaz JF
ACS Chem Biol; 2011 Aug; 6(8):789-99. PubMed ID: 21539341
[TBL] [Abstract][Full Text] [Related]
15. Structure-based approaches for the design of benzimidazole-2-carbamate derivatives as tubulin polymerization inhibitors.
Aguayo-Ortiz R; Cano-González L; Castillo R; Hernández-Campos A; Dominguez L
Chem Biol Drug Des; 2017 Jul; 90(1):40-51. PubMed ID: 28004475
[TBL] [Abstract][Full Text] [Related]
16. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Li W; Zhai B; Zhi H; Li Y; Jia L; Ding C; Zhang B; You W
Tumour Biol; 2014 Sep; 35(9):8883-91. PubMed ID: 24894670
[TBL] [Abstract][Full Text] [Related]
17. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells.
Azarenko O; Smiyun G; Mah J; Wilson L; Jordan MA
Mol Cancer Ther; 2014 Aug; 13(8):2092-103. PubMed ID: 24980947
[TBL] [Abstract][Full Text] [Related]
19. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability.
Kamath K; Wilson L; Cabral F; Jordan MA
J Biol Chem; 2005 Apr; 280(13):12902-7. PubMed ID: 15695826
[TBL] [Abstract][Full Text] [Related]
20. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
